Desidustat vs SSS17
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline
Desidustat · Oxemia
Marketed by Zydus Lifesciences and partners
NCT04012957 · Phase 3 · completed
The study was randomized and used an active darbepoetin comparator, but it was open-label and its primary outcome was change in hemoglobin, a surrogate laboratory measure rather than a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Hemoglobin level (24 weeks): Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382) (met)
Result source: NCT04215120
SSS17
Developed by Shenyang Sunshine Pharmaceutical
NCT07014631 · Phase 2 · completed
The study randomized 86 participants to SSS17 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in hemoglobin, a laboratory surrogate measure, and the comparison has not been reported, so no conclusion can yet be drawn about whether the endpoint was met.
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Desidustat | SSS17 |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT04012957 | —Not reported |
| UACR, % change | —Not posted · NCT04012957 | —Not reported |
| eGFR slope | —Not posted · NCT04012957 | —Not reported |
| Haemoglobin, change | 1.9 vs 1.8avs darbepoetinNCT040129571 other result
| —Not reported |
Kidney composite outcome
- Desidustat
- —Not posted · NCT04012957
- SSS17
- —Not reported
UACR, % change
- Desidustat
- —Not posted · NCT04012957
- SSS17
- —Not reported
eGFR slope
- Desidustat
- —Not posted · NCT04012957
- SSS17
- —Not reported
Haemoglobin, change
- Desidustat
- 1.9 vs 1.8avs darbepoetinNCT04012957
1 other result
- 0.9 vs 0.8 NCT04215120
- SSS17
- —Not reported
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SSS17: no structured comparison results are available for Chronic Kidney Disease.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Desidustat
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Desidustat's landscape · SSS17's landscape